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Abstract
Objectives: To measure the tocolytic effect of the combi-
nation of the oxytocin receptor antagonist atosiban with 
the β-mimetic agent fenoterol on human myometrium of 
pregnant women.
Methods: An in vitro study of contractility in human myo-
metrium at the Laboratory of the Department of Obstet-
rics, University  Hospital of Zürich, Switzerland, was 
performed. Thirty-six human myometrial biopsies were 
obtained during elective caesarean sections of singleton 
pregnancies at term. Tissue samples were exposed to 
atosiban, fenoterol and the combination of atosiban with 
fenoterol. Contractility was measured as area under the 
curve during 30  min of spontaneous contractions. The 
effect of treatment was expressed as the percentage of 
change from basal activity during 30 min of exposure. Dif-
ferences were calculated using a paired Wilcoxon signed-
rank test. An additive effect of dual tocolysis was assumed 
when no significant difference was detected between the 
observed and expected inhibition of dual tocolysis. When 
inhibition was greater or lower than expected, the dual 
combination was characterised as “synergistic” or “antag-
onistic”, respectively.
Results: Atosiban and fenoterol alone suppressed con-
tractions by a median of 43.2% and 29.8%, respectively. 
The combination of atosiban plus fenoterol was measured 
at a level of 67.3% inhibition. There was no significant dif-
ference in the expected (63.2%) and observed inhibition 
effect of dual tocolysis (P = 0.945).
Conclusions: This study demonstrated an additive effect 
of dual tocolysis of atosiban and fenoterol on human myo-
metrium in vitro, but no synergistic or antagonistic effect.
Keywords: in vitro; preterm delivery; tocolysis.
Introduction
Preterm birth remains a problem for obstetric care. It 
accounts for 11.1% of births globally, and affects an esti-
mated 14.9  million babies every year [1]. Preterm birth 
represents the single largest cause of mortality and mor-
bidity in newborn babies and is a major cause of mor-
bidity for pregnant women [2]. Data from developed 
countries showed an increase in the incidence of preterm 
births during the last decade. A population-based study 
in Denmark showed that the overall proportion of preterm 
deliveries increased by 22% from 1995 to 2004 [3].
Tocolytic agents play an essential role in hindering 
preterm deliveries. They have been shown to effectively 
delay delivery for at least 48  h, which enables adminis-
tration of antenatal corticosteroids to enhance fetal lung 
maturation, as well as intrauterine transfer of the fetus to 
a tertiary care centre [4]. There is evidence that prolong-
ing the pregnancy can decrease preterm delivery that is 
associated with severe infant morbidity and mortality, 
particularly during early gestation. Unfortunately, single 
tocolytic agents are not always effective at achieving this 
goal. Furthermore, some of these agents have substan-
tial side effects that necessitate treatment cessation [5]. 
As an alternative, investigations into the use of combin-
ing two tocolytic agents have been gaining interest. The 
aims are twofold: to find ways to augment the tocolytic 
effect in patients with persisting contractions despite the 
maximum dose of a single tocolytic agent, and to reduce 
side effects using a lower dose of each single agent in com-
bined therapies.
The main tocolytic agents currently in use alter myo-
metrial contractility through two different pathways. 
First, they affect the contractile proteins (usually the 
phosphorylation of myosin) in a similar way to β-mimetic 
agents, by intracellular accumulation of cyclic adenosine 
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monophosphate (cAMP). The second pathway is to act on 
intracellular calcium concentrations, which can be influ-
enced directly by calcium channel blockers or indirectly 
by preventing an increase in intracellular calcium via 
the inositol triphosphate production (IP3)-pathway, just 
as atosiban acts as an oxytocin receptor antagonist [5]. 
Simultaneous blockage of these two different pathways 
has been hypothesised as a promising combination for 
achieving an additive or even synergistic effect, with con-
siderable benefit for clinically high risk situations.
In animal models, the combination of the β-mimetic 
agent ritodrine with atosiban resulted in synergistic inhi-
bition of myometrial contractility, exceeding the additive 
effect [6]. While some physicians use this off-protocol 
combination therapy in complex situations in clinical 
practice, there is no experimental or clinical data about 
the effects in humans. The aim of this study was to analyse 
the in vitro tocolytic effects of the combination of atosiban 
with fenoterol in human myometrium of pregnant women. 
We hypothesised that due to different pathways of action 
an additive or even synergistic tocolytic effect could result.
Materials and methods
This in vitro study of contractility in human myometrium was per-
formed at the Laboratory of the Department of Obstetrics, University 
Hospital of Zürich, Switzerland between 2012 and 2016. Myometrial 
biopsies were obtained from 36 women at a mean age of 33 years (SD 
5.5)  during elective caesarean section at term. All patients included 
in the study gave written informed consent. Excluded from the analy-
sis were women who had tocolytic treatment within 2 weeks before 
caesarean section, previous caesarean section, preterm rupture of 
membranes, chorioamnionitis, preeclampsia or an infectious mater-
nal disease.
The applied in vitro model for evaluation of tocolytic agents has 
been previously described in detail [7, 8]. In summary, biopsies of 
myometrial tissue (5 g) were taken from the superior edge of the hys-
terotomy incision, immediately immersed in iced Ringer or modified 
Krebs solution (NaCl 118; KCl 4.7; CaCl2 2.48; KH2PO4 1.24; MgSO4 1.21; 
NaHCO3 24.9; glucose 10.0; EDTA 0.034 mmol/L) and then transported 
within 2 h to the laboratory for further processing. Longitudinal strips 
of muscle fibres (approx. 15 × 2 × 1 mm) were carefully prepared. Four 
strips were simultaneously mounted into different chambers of a 
myograph (DMT800MS Muscle Strip Myograph  system, DMT, ADIn-
struments GmbH, Aarhus, Denmark) and placed in a  jacketed organ 
bath with gas feed lines. A heating thermostat maintained the Krebs 
solution at a temperature of 37°C and continuous aeration with oxy-
carbon (5% CO2 and 95“/” 02, Pan Gas, Dagmarsellen,  Switzerland) 
maintained a pH level of approximately 7.40. Tension was applied to 
the strips to initiate spontaneous contractions. Isometric contrac-
tions were recorded by the myograph and transferred digitally by a 
transducer (power rennet 4/30).
After measuring basal contractility for 30  min (basal activ-
ity – spontaneous contractions), the experimental substance was 
added and contractions were recorded again for another 30  min. 
Strips were exposed to the following substances: (1) atosiban 
(450 ng/mL, Ferring Pharmaceuticals A/S, Copenhagen, Denmark), 
(2) fenoterol (2242  pg/mL, Boehringer Ingelheim Pharma GmbH 
& Co. KG, Ingelheim am Rhein, Germany), (3) a combination of 
atosiban and fenoterol, and (4) Krebs-Henseleit solution as an inter-
nal control. The concentration levels were determined based on the 
standard of care for clinical presentation of persisting contractions, 
despite administration of the maximum dose of tocolytic treat-
ment [9, 10]. To test the viability of the samples, there was a 30-min 
wash out period during which the strips recovered and were able to 
resume regular spontaneous contractions. If myometrial strips did 
not continually contract until this last step of the experiment, they 
were excluded from further analysis.
Recorded myograms were analysed using LabChart Pro 
( ADInstruments, Dunedin, New Zealand) software. Contractility was 
defined as “area under the curve” of contractions. The tocolytic effect 
was defined as percent inhibition of contractility. The expected effect 
of dual-agent tocolysis was calculated as the sum of inhibition pro-
duced by each drug alone. The expected additive tocolytic effect was 
compared to the observed effect and the following three scenarios 
were possible: (1) additive effect – no significant difference between 
expected and observe effect; (2) synergistic effect – observed effect 
significantly superior to expected effect; or (3) inhibitory effect – 
observed effect significantly inferior to expected effect.
The observed inhibition was compared to the expected inhibi-
tion using the paired Wilcoxon signed-rank test. Statistical analysis 
was conducted using Sigmaplot 12.0 (Systat Software Inc., San Jose, 
CA, USA). The level of statistical significance was set at P < 0.05.
The study was approved by the local Ethics Committee 
(Kantonale Ethikkommission Zürich, No. 2012-0258) on 7th of August, 
2012.
Results
The mean gestational age was 38  weeks (SD 0.8). The 
indications for caesarean section were breech position 
[11], psychosocial [11], pelvic disproportion [3], traumatic 
obstetric history [2], fetal malformation [1], maternal para-
plegia [1] and fetal transverse presentation [1].
A total of 36 experiments were performed, five of 
which were done to establish the protocol and to validate 
the concentrations of test substances. From the remain-
ing 31 biopsied tissue samples, eight had to be excluded 
because of insufficient or inconsistent contractions. As a 
result, 23 samples were available for analysis (n = 23).
Atosiban and fenoterol alone suppressed spontane-
ous contractions by a median of 43.2% and 29.8%, respec-
tively. The combination of atosiban plus fenoterol reached 
a median level of 67.3% inhibition. The expected effect of 
dual-agent tocolysis (63.2%) was not significantly differ-
ent from the observed effect (P = 0.945). Thus, an addi-
tive but not synergistic effect of dual tocolysis was found 
(Table 1, Figure 1).
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Likewise, the frequency of contractions was sup-
pressed by tocolytic agents at a similar scale. The expected 
effect of dual-agent tocolysis was not significantly differ-
ent from the observed effect (P = 0.71, data not shown).
Discussion
This is the first study to analyse the tocolytic effect of 
the combination of atosiban with fenoterol on human 
myometrium. While we demonstrated that dual tocolysis 
of atosiban plus fenoterol can achieve an additive effect 
to suppress contractions in spontaneously contracting 
human myometrium, a synergistic effect was not found.
The in vitro model is well established at our institute 
and internationally accepted in the literature as a means 
to evaluate the effect of single or dual tocolysis [6, 7, 11–14]. 
However, this in vitro model can only approximate the 
clinical situation in which preterm birth is a pathophysi-
ologically heterogenous syndrome [15].
The rationale for a possible benefit of combining two 
tocolytic agents is based on two main assumptions: (1) the 
combination of agents leads to an additive or even syn-
ergistic effect with a superior clinical outcome in cases 
when a single agent is not effective, and (2) the combina-
tion of tocolytic agents may permit a dose reduction of 
both agents while having the same tocolytic effect, which 
would lead to a decrease in maternal and fetal side effects. 
This may also decrease the costs associated with tocolysis 
(high costs are a limiting factor for the use of atosiban). 
Tocolytics act through different pathways to inhibit 
uterine contractile activity. β-Mimetics induce relaxation 
through intracellular accumulation of cAMP [16]. Calcium 
channel blockers directly prevent influx of calcium ions 
responsible for smooth muscle cell contraction, whereas 
oxytocin receptor antagonists act indirectly to prevent the 
rise of intracellular calcium concentration in response to 
the oxytocin-induced increase in lP3 [17]. Simultaneous 
blockage of different pathways could result in a synergis-
tic effect capable of potentiating the uterine relaxation 
induced by each single drug.
Despite the possible advantages, only a few clinical 
studies have evaluated the effects of a combination of 
tocolytics. Evidence for the effect of combined tocolytics 
has been reviewed recently in a Cochrane analysis [18]. 
No difference in infant outcomes was reported for any of 
the test combinations. Only the combination of ritodrine 
plus vaginal progesterone showed a positive effect. The 
authors noted that there were no trials using a combi-
nation regimen with widely used tocolytic agents, such 
as calcium channel blockers or oxytocin receptor antago-
nists. Recently, a combination of salbutamol and nifedi-
pine was tested in a small prospective cohort study [19]. 
The authors found no significant clinical difference when 
salbutamol was added before additional adverse effects 
were experienced.
While the paucity of clinical studies evaluating a 
combination of tocolytic agents may be due to ethical 
considerations about enrolling pregnant women at high 
risk for preterm birth in randomised controlled trials, 
in vitro models allow for testing of substances on myome-
trium to identify the most promising combinations before 
in vivo testing. To date, seven in vitro studies have been 
published evaluating the effects of combining tocolytics 
on isolated myometrium. The combination of β-mimetics 
with nifedipine demonstrated inhibition of contraction 
superior to either agent alone [20, 21]. Doret et al. were the 
first to classify the tocolytic effect of a combination to be 
Table 1: Percent inhibition of spontaneous contractions.
Median 25%Q 75%Q
Atosiban alone 43.2 3.2 60.7
Fenoterol alone 29.8 9.6 73.0
Calculated additive tocolytic effect 63.2 13.6 95.9
Measured additive tocolytic effect 67.3 23.3 93.5
Control −11.4 −40.1 21.2
Atosiban Fenoterol
Calculated effect
dual tocolysis
Observed effect
dual tocolysis Control
–60.0
–40.0
–20.0
0.0
20.0
40.0
60.0
80.0
100.0
120.0
%
Figure 1: Inhibition of spontaneous contractions after addition of 
atosiban or fenoterol alone, atosiban and fenoterol in combination 
and calculated additive reduction.
Data are expressed as median and interquartile range.
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antagonistic, additive or synergistic, as described above. 
The authors could demonstrate that in rat myometrium 
the combinations of either rofecoxib or atosiban with 
ritodrine had a synergistic effect while other combi nations 
resulted in an additive effect [6, 22]. Two more recent 
in vitro studies on human myometrium demonstrated that 
atosiban and nifedipine resulted in an additive tocolytic 
effect and nifedipine with ritodrine produced a signifi-
cantly greater inhibition of contractility than each drug 
alone [11, 14]. In conclusion, there were two promising 
combinations that exhibited a synergistic inhibition for 
myometrial activity: ritodrine with rofecoxib and ritodrine 
with atosiban. Rofecoxib is not used in clinical practice 
as a tocolytic agent as severe adverse effects have been 
described [23].
Therefore, the combination of a β-mimetic and 
atosiban seemed to be the most promising at achieving 
maximal tocolytic effects in clinically difficult situations 
when a single agent was not sufficient to supress con-
tractions, or when side effects or monetary restrictions 
prevent maximal dosage of single agents. Considering the 
promising results in the animal model, we conducted our 
analysis to project the possible in vivo reaction [9, 10].
In our study we tried to approximate a clinical 
situation by using human myometrium and drug con-
centrations measured in vivo. However, there are no avail-
able data about pharmacocinetic interactions between 
atosiban and fenoterol. One study analysed the interac-
tion between atosiban and the β-blocking agent lalol. 
While Cmax was reduced and tmax was prolonged for 
labetalol, the authors concluded that bioavailability was 
not influenced in a clinically relevant matter [24]. Even 
though the β-mimetic fenoterol is not comparable to the 
β-blocking labetalol, we cannot exclude an interaction 
in vivo and our in vitro model is not sufficient for a final 
assessment of the effectiveness of dual tocolysis. Further-
more, it is known that receptor mediated contractility of 
human myometrium changes in the course of pregnancy 
[25]. Myometrial bio psies used for our experiments were 
taken at term during elective caesarean sections to guar-
antee the ethical  standard of an informed consent that 
was requested the day before surgery. Our results should 
be interpreted considering the possible difference in con-
tractility and receptor expression in preterm myometrium.
Test substances were applied on spontaneously 
contracting human myometrial samples. This was con-
trary to methods of other investigators using a model of 
 oxytocin-induced contractions to analyse tocolytic effects 
[12–14]. In preliminary experiments, however, we found 
that this approach was not feasible for a study design 
including atosiban as oxytocin-induced contractions 
were already maximally supressed by the oxytocin recep-
tor antagonist atosiban (data not shown). In our in vitro 
human model, however, a synergistic effect, as described 
in rat myometrium, could not be confirmed.
Clinical studies are needed to examine the in vivo 
effects, possible pharmacocinetic interactions and safety 
of the most promising combinations of tocolytics in the 
in vitro model, such as β-mimetic/atosiban or nifedipine/
atosiban. Further in vitro experiments could also evaluate 
a combination of three substances including progesterone.
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